Furthermore, although serum GLP-1 and DPP-IV levels in the T2DM-MLE group did not reach the levels observed in the sitagliptin-treated (T2DM-SG) group, MLE treatment still produced significant improvements in incretin-related parameters. The gene discussed is GCG; the disease is type 2 diabetes mellitus.